Prognosis
Oxford Malaria Vaccine Trial Points to Disease ‘Game-Changer’
- Vaccine, trialed in 450 children, shows 77% effectiveness
- Serum Institute deal promises large-scale and low-cost supply
Photographer: Olympia De Maisont/AFP/Getty Images
This article is for subscribers only.
The first malaria vaccine to meet a World Health Organization specified goal of more than 75% efficacy has been developed by scientists at the University of Oxford, a potentially significant step toward defeating the disease.
Finding more effective inoculations against the mosquito-borne disease has been a critical goal in fighting an infection that kills about 400,000 people a year, largely in sub-Saharan Africa, with most being children under the age of five.